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Abstract
Background: Previous studies may have overestimated morbidity and mortality due to Klebsiella pneumoniae
producing carbapenemase (KPC) Klebsiella pneumoniae infections because of difficulties in modeling patient
comorbidities. This pilot study sought to evaluate KPC virulence by combining clinical and Galleria mellonella
models in patients with K. pneumoniae blood stream infections (BSIs).
Methods: G. mellonella were inoculated using KPC(+) and KPC(−) isolates from these patients. Extent and rapidity of
insect mortality was analyzed. Patients were stratified by KPC BSI status. Clinical outcomes of mortality and length
of stay post-infection for survivors (LOS) were analyzed. Median virulence scores calculated from the insect studies
were imputed in the clinical model.
Results: The in-vivo model revealed greater mortality in KPC(−) isolates (p < 0.001). Fifteen patients with KPC(+) BSI
were matched with 60 patients with KPC(−) BSI. Hospital mortality was greater in the KPC(+) group versus the KPC(−)
group (OR 3.79, 95% CI 1.00 - 14.34). LOS was longer in the KPC(+) group (p < 0.01). Conversely the virulence score
attenuated the association between KPC(+) status and mortality and LOS in the final translational models.
Conclusions: KPC(+) status was associated with decreased virulence in GM. Opposite findings were observed in
patients. This pilot study demonstrates that measured virulence from GM may differ from human estimates of virulence.
Keywords: Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae, Galleria mellonella, Virulence,
Mortality, Resistance
Background
Klebsiella pneumoniae producing carbapenemase (KPC)
Klebsiella pneumoniae are an emerging pathogen with
the propensity to cause poor patient outcomes and high
mortality [1]. There is controversy surrounding the rea-
sons for these poor outcomes, including debate as to
whether carriage of the resistance gene makes the or-
ganism more or less virulent. Clinical studies of KPC
virulence to date have found discordant estimates of
pathogenicity [2-6]. Furthermore, difficulties in modeling
complex patient factors may have confounded the ability
to discern effects on attributable mortality. The magnitude
of patient mortality attributed to KPC may have also dif-
fered due to various study designs [7].
To attempt to obtain a more reliable estimate of the mag-
nitude of KPC virulence, we created a pilot study that
employed a validated Galleria mellonella host-pathogen
interaction model using blood stream infection (BSI) iso-
lates from KPC(+) and KPC(−) patients. Galleria mellonella
is the caterpillar of the Greater Wax Moth and is well vali-
dated as an in-vivo model because of its humoral and cellu-
lar immune response pathways [8] and a clear correlation
of organism virulence with mammalian models [9-11].
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Furthermore, the organism K. pneumoniae has been exten-
sively validated in the G. mellonella model in recent efforts
[11,12]. Advantages of the G. mellonella model include the
ability of G. mellonella to be injected with precise inocula
and to be maintained at temperatures that mimic human
host conditions [9,13-17]. Since the insects can be infected
prospectively and randomly, this insect model also eludes
the need to correct for disproportionate and complex pa-
tient comorbidities between KPC(+) and KPC(−) groups.
This novel study methodology study sought to quanti-
tatively evaluate KPC virulence using a clinical transla-
tional approach: first, by assessing the relative virulence
of representative KPC(+) and KPC(−) K. pneumoniae
isolates from the clinical study with the G. mellonella
host-pathogen interaction model; second, by determin-
ing the clinical virulence of KPC(+) K. pneumoniae
blood stream infections by comparing KPC(+) to KPC(−)
blood stream infections while controlling for confounding
variables with standard clinical data modeling techniques;
and third, by using the virulence score obtained from the
insect model to re-inform the clinical model to obtain a
corrected effect of KPC(+) virulence. It should be noted
that the last effort is pilot in nature.
Methods
Organism identification and susceptibility testing
Organism identification was completed using the Vitek II
system (bioMérieux, Balmes-les-Grottes, France) and man-
ual biochemical identification when necessary. Antimicro-
bial susceptibility testing was performed on all isolates
by the Vitek II system or Etest (AB bioMérieux, Solna,
Sweden). Susceptibilities were categorized according to
Clinical and Laboratory Standards Institute (CLSI) guide-
lines [18]. Isolates were classified as KPC(+) or KPC(−),
with KPC(−) isolates being pan-susceptible except for
ampicillin. KPC positive or negative status was confirmed
using common primers for KPC 1, 2, and 3 (forward
primer: 5′-TGT CAC TGT ATC GCC GTC-3′, reverse
primer: 5′-CTC AGT GCT CTA CAG AAA ACC-3′).
Molecular typing by pulsed field gel electrophoresis
Pulsed field gel electrophoresis (PFGE) was performed
on all K. pneumoniae isolates to identify potential clonal
spread. Genetic similarities of intra-patient isolates were
determined by visual inspections of DNA banding pat-
terns using the criteria of Tenover et al. [19] with iso-
lates having 3 or fewer differing bands labeled as closely
related, those with 4 to 6 differing bands considered pos-
sibly related, and those with more than 6 bands different
considered genetically distinct.
Galleria mellonella model
Each KPC(+) bloodstream isolate from the clinical study
was randomly matched to one KPC(−) isolate from the
clinical study. Twelve randomly selected insects weigh-
ing between 250–350 mg were selected for each isolate
(Vanderhorst, Inc, St. Mary’s, OH). The insects were
inoculated by injecting 1 x 106 CFU per 10 microliter ali-
quot into the hemoceol via the rear left proleg using a
10 μL Hamilton animal syringe (Hamilton Co., Reno, NV,
USA). Colony counts were performed by serial dilution
with ultimate plating on blood agar (Remel, Lenexa, KS).
Individual colonies were enumerated after 18–24 hours
incubation at 38°C in ambient air. Any experiment with
a colony count outside of a half log10 deviation was re-
peated. Phosphate buffer solution (placebo) injection
controls and controls receiving no injection were used
to evaluate trauma and attrition, respectively. Results
were not included if greater than or equal to two insects
died in either of the control groups [15]. The insects
were incubated at 37°C in atmospheric air and observed
every 24 h for 5 days. One common isolate was used for
each experiment to control for inter-experiment insect
robustness. Experiments were performed in duplicate
and repeated in the case of discordance. Representative
results are reported for all final experiments meeting in-
clusion criteria.
Clinical study design and patient selection
A combined clinical and translational study comprised
of a retrospective clinical study and an insect viru-
lence model was conducted at Northwestern Memorial
Hospital in Chicago, IL. Patients at least 18 years of age
and with at least one positive blood culture for Klebsi-
ella pneumoniae identified from March 2010 through
December 2011 were eligible. Only the first isolate per
patient during the study period was considered for in-
clusion. Four control KPC(−) patients were matched to
each KPC(+) patient in order to optimize the relative
gains in power associated with each additional patient
included [20,21]. This study was reviewed and approved
by the Northwestern Memorial Hospital and Midwestern
University Institutional Review Boards with a waiver of
informed consent.
Patient data collection
Patient demographics and data variables were collected
using inpatient electronic medical records, pharmacy
databases, and clinical microbiological databases. Patient
demographics included age, gender, modified Acute Physi-
ology and Chronic Health Evaluation (APACHE) II score
[22,23], prior hospitalizations, absolute neutrophil count
(ANC) of less than 500 cells/mm3, renal dysfunction, hep-
atic dysfunction, diabetes, current immunosuppression,
and length of stay prior to positive culture. Other clinical
variables included time to directed therapy, number of
clinical sites with positive cultures for K. pneumoniae, and
total days of antibiotics.
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Clinical definitions
Hepatic dysfunction was defined as any liver function test
value greater than 3 times the upper limit of normal at the
time of culture [24]. Renal dysfunction was defined as
chronic kidney disease, dialysis, or an increase in serum
creatinine of 0.5 mg/dL or 50% at the time of culture as
compared to a previous value [25,26]. Current immuno-
suppressive therapy was defined as the patient receiving
therapy with any corticosteroids or chemotherapy at the
time of admission. Since optimal and appropriate therapy
is not fully elucidated for KPC, we assessed adequacy in
several manners. Directed therapy was defined as any anti-
biotic given to a patient in a directed manner after culture
results were available. Time to directed therapy was de-
fined as the time in hours from the culture draw to the re-
ceipt of antibiotic therapy. As in-vitro activity of antibiotics
is not entirely predictive of in-vivo outcomes for carbape-
nemase producing organisms, we assessed all drugs given
in a directed manner (e.g. meropenem could be directed
treatment for a KPC producing organism) [27,28].
Statistical analysis
Galleria mellonella model analysis
The primary outcome for the insect model was rapidity
and extent of mortality of the G. mellonella assessed
with Kaplan-Meier survival curves and log rank tests.
Clinical analysis
The outcomes for the clinical model were: hospital mor-
tality of patients according to KPC status, duration of in-
fection, carbapenem use post culture, and length of stay
post-infection for survivors. For bivariate comparisons,
the Student’s t-test, Wilcoxan Rank Sum, Chi-square,
and Fisher’s Exact tests were used as appropriate. Multi-
variate models were created to assess the independent
primary modifier of KPC status on mortality and length
of stay post-infection for survivors. To find the most parsi-
monious and explanatory model, relevant confounders
were controlled using a forward stepwise procedure by
adding variables with a plausible relationship to the
dependent outcomes and significant at the p < 0.2 level in
bivariate analysis. Variables of interest, KPC status and
virulence score, were forced as initial bivariate compari-
sons. Models were assessed for optimization and com-
pared against the model with one additional variable. For
linear models, normalized variable versus residual plots
were examined, and variables unduly influenced by one or
two outliers (i.e. slope essentially defined by one or two
points) were removed from the model. The removal of
these variables was done to conservatively attempt to
see if KPC status retained a significant relationship with
length of stay post-infection for survivors after correcting
for the virulence factor and other highly significant
variables. For logistic regressions, the final model was
the most parsimonious model that was significantly dif-
ferent from the others (i.e. objective factor ≥ 3.84 for
models differing by one exploratory variable for logistic
regression and an increase in the adjusted-r2 value for
linear regression).
Combined model analyses
To conduct the pilot analyses imputing virulence scores,
multivariate models from the clinical study were re-
informed using virulence scores obtained from the insect
model (i.e. area under the individual insect mortality
curve scores were calculated from the Kaplan-Meier
curves). Resultant virulence scores could range from 0–
60 dead insect days. On each day a total of 12 insects
were eligible to be dead or alive. Therefore the maximum
score is 60 (12 insects x 5 days; 100% insect mortality on
day 1), and the minimum score is zero (0 insects x 5 days;
0% insect mortality at day 5). Thus, higher scores indicate
greater virulence. All tests were two-tailed and significance
was set at p < 0.05. All statistical analyses were performed
with Intercooled Stata, version 11.1 (Statacorp, College
Station, TX).
Results
A total of 17 KPC(+) blood stream infections were identi-
fied during the study period and considered for inclusion.
Of these cultures, 2 were duplicates and were excluded
from the analysis. Therefore 15 patients with KPC(+)
blood stream infections were matched with 60 patients
with KPC(−) blood stream infections and were included in
the analysis. All isolates were genetically distinct per PFGE
analysis (data not shown).
Insect model results
In the G. mellonella model at 24 hours, KPC(−) K. pneu-
moniae isolates killed approximately 50% of the larvae
compared with 25% mortality with larvae injected with
KPC(+) K. pneumoniae isolates. This difference persisted
throughout the five day study period (Figure 1). Accord-
ingly differences in mortality over five days were observed
between the KPC(+) and KPC(−) K. pneumoniae isolates
(p < 0.001). The median virulence score for KPC(+) isolates
was 13 insect days (IQR 3–23) and 50 insect days (IQR
31–56) for the KPC(−) isolates. A median virulence score
of 50 insect days was utilized for the remaining 45 KPC(−)
patients.
Clinical results
The mean age, number of female patients, and modified
APACHE II score were similar between the KPC positive
and negative groups (Table 1). There were a larger per-
centage of patients receiving current immunosuppressive
therapy in the KPC(−) group (18.3% vs. 6.7%), however,
this was not statistically significant. A greater percentage of
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patients in the KPC(+) group had prior hospitalizations
(80% vs. 46.7%, p = 0.02). The KPC(+) group also exhibited
a significantly longer length of stay prior to positive cul-
ture, length of antibiotic treatment, and more frequent
K. pneumoniae cultured from more than one site (p < 0.01
for all). No difference was found between the groups for
time to directed therapy. Clinical characteristics and out-
comes of KPC(+) patients are shown in Table 2.
Previously hospitalized patients and those with renal
dysfunction were less likely to survive their hospital stay
(p < 0.01 for both; Table 3). The hospital length of stay
prior to positive culture was also longer in the non-
survivor group (p < 0.01). The median time to directed
therapy was zero days (interquartile range [IQR] 0–5.25)
in the non-survivors and 6 days (IQR 3–15.5) in the sur-
vivor group (p < 0.01).
The outcome of hospital mortality was greater in the
KPC(+) group (n = 5, 33.3%) versus the KPC(−) group
(n = 7, 11.7%; p = 0.055; Table 4); however, this difference
narrowly failed to meet the threshold for statistical sig-
nificance. There was also a larger percentage of KPC(+)
patients that received a carbapenem post culture (n = 6,
40%) than the KPC(−) group (n = 4, 6.7%; p < 0.01). The
median length of stay post infection for survivors was
18.5 days (IQR 15–22) in the KPC(+) group compared
with 7 days (IQR 6–13) in the KPC(−) group (p < 0.01).
The duration of infection did not differ significantly be-
tween the groups.
Multivariate and translational pilot model results
For the outcome of mortality, in the first multivariate
model, KPC(+) status was associated with increased
Figure 1 Kaplan-Meier survival for G. mellonella inoculated with K. pneumoniae isolates showing mean values (1A) and 95% confidence
intervals (1B). KPC = Klebsiella pneumoniae producing carbapenemase.
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odds of mortality, (OR 3.79, 95% CI 1.00 – 14.34;
Table 5). In the second multivariate model, modified
APACHE II score was associated with a 13% nonsignifi-
cant increase in mortality for each increase of 1 in
APACHE II score (OR 1.13, 95% CI 0.97-1.32), and
KPC(+) status had a similar, but less significant associ-
ation (OR 3.34, 95% CI 0.84-13.27) relative to the first
model. In the third model, virulence score attenuated
the association between KPC(+) status and mortality
(OR 2.51, 95% CI 0.2-31.1). When virulence score was
assessed alone with mortality, each increase of viru-
lence score was associated with a downward trending
3% drop in mortality (0.97, 95% CI 0.94-1.00). Probabil-
ities of death calculated from the odds ratio can be
found in Figure 2.
For the outcome of length of stay post-infection for
survivors, in the first multivariate model, KPC(+) status
was associated with an increased length of stay (2.11 days,
95% CI 1.38-3.23, p < 0.01). This association did not remain
significant when the virulence score was added to the
model (1.83 days, 95% CI 0.96-3.5, p = 0.066) or when vari-
ables were added to the model according to the pre-
specified building criteria (1.67 days, 95% CI 0.89-3.12,
p = 0.11). As additional relevant variables were added to
the model, the significance between the mean lengths of
stay between KPC(+) and KPC(−) groups diminished as
demonstrated in Figure 3.
Discussion
This study found decreased virulence for KPC (+) iso-
lates compared to KPC(−) isolates in a G. mellonella
model. The study analyzing patient outcomes from the
patients that contributed the isolates found the opposite
association at the bivariate level (i.e. KPC (+) patients
experienced greater mortality). Specifically, this clinical
study identified a 20% absolute increase in hospital
mortality for KPC(+) patients. Minimally, the discor-
dances between these two models should give researchers
pause. Our pilot study imputing a virulence score, which
should be interpreted with caution due to low power,
demonstrated that attributable virulence in patients was
decreased when considering the insect model virulence re-
sults. In a separate analysis designed to limit the number
of predictor variables entered into the multivariate logistic
model, increasing organism virulence score from the
G. mellonella model was associated with downward
trending mortality rates at the bivariate level. The length
of stay post-infection for survivors was 11.5 days longer
in the KPC(+) group when considering the unadjusted
model. Similarly here, the magnitude of difference and
association was attenuated with the addition of the
virulence score. The G. mellonella model indicated that
KPC(−) K. pneumoniae isolates were more virulent than
KPC(+) K. pneumoniae isolates.
G. mellonella larvae have been shown as a validated
invertebrate host model for deciphering virulence in
K. pneumoniae [11,12] as well as a number of other bacter-
ial pathogens including: Listeria spp. [29], Staphylococcus
aureus [16], Acinetobacter baumannii [15], Pseudomonas
aeruginosa [30], among others. Several studies have also
used the G. mellonella model to demonstrate the virulence
between different strains or genetic mutations of organisms
[11,15,16]. Results from this host-pathogen interaction
model have also been shown to produce similar results to
mouse models with K. pneumoniae [11]. Importantly
known K. pneumoniae virulence factors such as capsule
polysaccharide and biochemical manipulations to Lipid A
when studied as knock-out mutants and compared to
isogenic parent isolates, demonstrate that G. mellonella
models are highly capable of discerning virulence [11].
Concordance has been seen with other organisms using
virulence models with G. mellonella and higher order
animal studies. Wand et al. studied the virulence of sev-
eral species of Burkholderia and found that the results
found in the G. mellonella model reflected those found
in a similar murine infection model [31]. Jander et al.
reported a positive correlation (p < 0.001) of virulence
patterns between Pseudomonas aeruginosa isolates tested
in G. mellonella and a burned mouse model [10].
Prior work, as described below, suggests that patients
with KPC(+) K. pneumoniae blood stream infections
have a higher mortality than patients with KPC(−) isolates.
Table 1 Demographic and clinical characteristics of
patients with K. pneumoniae blood stream infections






Age (mean, SD) 59.5 (11.3) 59.6 (17) 0.98
Gender, female 32 (53.3) 8 (53.3) 0.99
Modified APACHE II score (mean, SD) 12.1 (5.4) 10.8 (4.2) 0.31
Prior hospitalization 12 (80) 28 (46.7) 0.02
Neutropenic 1 (6.7) 1 (1.7) 0.36
Renal dysfunction 3 (20) 10 (16.7) 0.72
Liver dysfunction 2 (13.3) 5 (8.3) 0.62
Diabetes 3 (20) 10 (16.7) 0.72
Current immunosuppressive therapy 1 (6.7) 11 (18.3) 0.44
LOS prior to positive culture
(median, IQR)
2 (1–12) 1 (1–1) <0.01
Time to directed therapy (hrs)
(median, IQR)
4 (0–24) 6 (3–13) 0.46
K. pneumoniae cultured from >1 site 11 (73.3) 19 (31.7) <0.01
Total days of antibiotics post infection
(median, IQR)
13 (8–18) 6.5 (4–10) <0.01
Note: Data are no. (%) of patients unless otherwise indicated.
KPC = Klebsiella pneumoniae producing carbapenemase, APACHE = Acute
Physiology and Chronic Health Evaluation, LOS = length of stay, SD = standard
deviation, IQR = interquartile range.
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Based upon the results of this study, the higher mortality
may be due to patient factors and not virulence of the
resistant organism. In the G. mellonella model, KPC(+)
K. pneumoniae isolates were less virulent than KPC(−)
isolates; there may be a fitness cost to carriage of the
resistant plasmid, or less fit organisms might be more
likely to acquire the resistance. While additional study is
certainly needed, the results of this pilot study suggest
that it might not be the virulence of KPC(+) K. pneumo-
niae that leads to poor patient outcomes.
Previous studies have evaluated outcomes of patients
with KPC(+) K. pneumoniae blood stream infections;
however, these studies used study designs different from
ours. Borer et al. conducted a matched, retrospective,
cohort study and found a 50% attributable mortality rate
for KPC(+) K. pneumoniae blood stream infections when
compared to hospitalized patients that were infected but
without bacteremia [3]. In a case–control study evaluating
patient outcomes, Mouloudi et al. reported in-hospital
mortality of 68% in the KPC(+) K. pneumoniae blood
stream infection group compared to 41% in the carba-
penem susceptible K. pneumoniae group and 44% in the
metallo-beta-lactamase producing K. pneumoniae blood
stream infection group [4]. Similarly, Ben-David et al. con-
ducted a retrospective cohort study of patients with KPC
(+) K. pneumoniae blood stream infections compared to
Table 2 Clinical characteristics and outcomes of KPC(+) patients















55 10 Vancomycin, tobramycin Lung >8 8 ≥16 None Died
79 18 Ciprofloxacin PICC line,
wound
>8 8 ≥16 Meropenem Died
68 13 Vancomycin, meropenem Lung/GU Not done 2 4 Meropenem Died
65 22 Meropenem, cefepime,
gentamicin, vancomycin
























64 9 Ciprofloxacin, meropenem,
vancomycin, aztreonam,
tigecycline









58 13 Vancomycin, piperacillin/
tazobactam, tigecycline
PICC line 32 16 Not done Cefepime, amikacin Transfer
to LTAC
55 8 Vancomycin, meropenem PICC line,
wound









67 15 Cefepime, ciprofloxacin,
gentamicin, linezolid
GU likely >8 4 2 Cefepime, gentamicin Transfer
to rehab
52 2 Ciprofloxacin, cefazolin,
vancomycin






GU = genitourinary, GI = gastrointestinal, PICC = peripherally inserted central catheter, LTAC = long term acute care, Rehab = rehabilitation organization.
*Directed therapy was defined as antibiotics received after culture results were available.
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extended spectrum beta-lactamase (ESBL) producing K.
pneumoniae blood stream infections and carbapenem sus-
ceptible K. pneumoniae blood stream infections [2]. The
authors found that infection-related mortality was signifi-
cantly higher among patients with KPC(+) infections com-
pared to ESBL producing or carbapenem susceptible
infections (48%, 22%, and 17%, respectively). All three of
these studies have found a higher mortality rate in carba-
penem resistant blood stream infections, but like all clin-
ical outcomes studies, they may suffer from an inability to
completely correct for all comorbidity variables. Our use
of the G. mellonella model allowed for KPC status to be
isolated as the only changing variable.
This study analyzed the virulence of K. pneumoniae
based on KPC status as a clinical variable and has shown
that KPC(+) status was not associated with mortality
when the virulence score was included in the model.
Virulence was directly calculated from a translational in-
vivo model in which all variables were held constant ex-
cept for KPC status. Prospective group assignment in
the insect model allowed unknown confounders to be
balanced between the groups and was able to provide an
unbiased estimate of the effect of KPC status.
Studies conducted by Zarkotou et al. [6] and Tumbarello
et al. [5] both found that increasing APACHE scores were
risk factors for mortality in patients with KPC(+) K. pneu-
moniae blood stream infections. This would indicate
that patient factors other than resistance may drive
poor patient outcomes. Similarly, Ben-David et al. and
Mouloudi et al. reported that increasing Pitt bacteremia
score, Charlson score, and Sequential Organ Failure As-
sessment (SOFA) score were independent risk factors for
mortality, respectively [2,4]. Both of these studies also
found that carbapenem resistance was an independent
risk factor for mortality. These studies suggest that KPC(+)
Table 3 Demographic and clinical characteristics of
patients with K. pneumoniae blood stream infections






Age (mean, SD) 58.8 (16.6) 64 (11.7) 0.30
Gender, female 32 (50.8) 8 (66.7) 0.36
Modified APACHE II score (mean, SD) 10.6 (4.3) 13.2 (4.9) 0.07
Prior hospitalization 29 (46) 11 (91.7) <0.01
Neutropenic 2 (3.2) 0 (0) 0.99
Renal dysfunction 7 (11.1) 6 (50) <0.01
Liver dysfunction 6 (9.5) 1 (8.3) 0.99
Diabetes 7 (11.1) 4 (33.3) 0.07
Current immunosuppressive therapy 10 (15.9) 2 (16.7) 0.99
LOS prior to positive culture
(median, IQR)
1 (1–1) 10.5 (2.5-23) <0.01
Time to directed therapy (hrs)
(median, IQR)
6 (3–15.5) 0 (0–5.25) <0.01
K. pneumoniae cultured from >1 site 24 (38.1) 6 (50) 0.44
Total days of antibiotics post infection
(median, IQR)
7 (4–14) 9 (5–15.5) 0.56
KPC(+) status 10 (15.9) 5 (41.7) 0.055
Note: Data are no. (%) of patients unless otherwise indicated.
KPC = Klebsiella pneumoniae producing carbapenemase, APACHE = Acute
Physiology and Chronic Health Evaluation, LOS = length of stay, SD = standard
deviation, IQR = interquartile range.
Table 4 Outcomes of patients with K. pneumoniae blood






In-hospital mortality 5 (33.3) 7 (11.7) 0.055
Duration of infection (median, IQR) 3 (3–4) 3 (3–5) 0.74
Carbapenem used post culture 6 (40) 4 (6.7) <0.01
LOS post infection, survivors
(median, IQR)
18.5 (15–22) 7 (6–13) <0.01
Note: Data are no. (%) of patients unless otherwise indicated.
KPC = Klebsiella pneumoniae producing carbapenemase, IQR = interquartile range.
Table 5 Multivariate analyses for risk factors for in-hospital
mortality of patients with K. pneumoniae blood stream
infections
Model Variable Mortality OR
(95% Confidence interval)
p-value
1 KPC(+) status 3.79 (1.00 - 14.34) 0.05
2 KPC(+) status 3.34 (0.84 - 13.27) 0.09
Modified APACHE II 1.13 (0.97 - 1.32) 0.12
3 KPC(+) status 2.51 (0.20 - 31.14) 0.48
Modified APACHE II 1.13 (0.97 - 1.32) 0.13
Virulence score 0.99 (0.93-1.06) 0.79
KPC = Klebsiella pneumoniae producing carbapenemase, APACHE = Acute
Physiology and Chronic Health Evaluation.
Figure 2 Probability of patient death according to Galleria
mellonella virulence score.
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K. pneumoniae are being isolated from critically ill patients,
and it may be impossible with conventional clinical study
methodologies to statistically separate out the attributable
virulence from KPC status.
One of our statistical findings may require additional
explanation. The bivariate logistic regression model, util-
izing the Chi-square test, identified a significant effect of
KPC on mortality (p = 0.050). The same data analyzed
with the more conservative Fisher’s Exact test resulted
in findings with p = 0.055. While bivariate logistic regres-
sion is appropriate for multivariate model building, the
Fisher’s Exact test is mathematically most appropriate.
Despite interpretive differences, the findings demon-
strate a trend towards statistical significance that is con-
sistent with previous literature reporting that KPC(+)
status portends increased mortality. Had our sample size
been larger, the increased study power would have likely
resulted in statistical significance (i.e. p < 0.05) regardless
of the test used.
While we believe that this novel methodology can im-
prove effect estimates in statistically complex clinical
data models, this pilot study has limitations that must be
considered. First, the clinical study was retrospective
and had a limited number of patients available. Still, the
G. mellonella studies demonstrated decreased virulence
for KPC(+) strains), and minimally the results demonstrate
discordance between the models. Our imputation model
attempted to combine these results, but care should be
taken in interpreting these results until a larger study can
confirm results. The limited patient enrollment concern
was partially addressed by matching KPC(+) patients on a
1:4 basis with KPC(−) patients in order to increase the
sample size, yet numbers were constrained. Unfortunately,
the model cannot easily be improved by simply add-
ing patients. Our data are highly unique because KPC
blood infections remain a rare event. For instance, the
CDC estimated that there are only 9,300 cases [32] of
carbapenem-resistant Enterobacteriaceae infections in
the United States per year. Only a fraction of these are
KPC and even a smaller fraction is bloodstream isolates.
Thus our numbers are quite large for a single center
study. To further illustrate this point, 386 Enterobacteria-
ceae blood stream infections occurred at our 897-bed,
tertiary-care, academic center in 2012. Of these, only 6
isolates were KPC. Multicenter trials may be necessary
for future analyses.
Second, there may have been inter-experimental vari-
ation in the robustness of the G. mellonella; however, we
accounted for this by using an inter-experimental con-
trol isolate to in order to adjust for any differences in
insects. Third, the potential exists for differences in re-
gional strains of K. pneumoniae; a larger multi-center
study could address organism epidemiology. Fourth, it is
possible that the G. mellonella results may not correlate
with human outcomes, but this possibility is less likely
given the translatability of the G. mellonella model with
other bacterial virulence studies [12-17] and animal
studies [10,11]. Fifth, optimal therapy for these infections
has not been fully defined, and the effect of antibiotic ther-
apy on survival is difficult to assess in this study due to
limited power. Finally, due to 1:1 matching of isolates for
the insect model, median virulence scores were extrapo-
lated for 45 patients. However, the findings obtained when
we analyzed a subset of 1:1 matched patients (i.e. patients
for which actual virulence scores were obtained and not
calculated) were concordant to those of the entire cohort
(data not shown).
Conclusions
In this study, results from the insect model indicated
that KPC(+) K. pneumoniae isolates were less virulent
than KPC(−) K. pneumoniae isolates. KPC(+) status was
associated with a 20% absolute increase in hospital
mortality for patients at the bivariate level. This finding
was attenuated when measured insect virulence was
imputed into the model. Similarly, the length of stay
post- infection for survivors was significantly longer in
the KPC(+) group, but again the virulence score attenu-
ated the association. Our novel pilot methodology sug-
gests that previous clinical studies may have overestimated
Figure 3 Multivariate analysis adjusted length of stay post
infection (mean, 95% CI) for KPC(+) and KPC(−) K. pneumoniae
blood stream infections. *Length of stay post infection for
survivors was modeled as a natural log transformed variable. It is
reported as inverse natural log for ease of interpretation. **Model 1:
Bivariate LOS for KPC(+) and KPC(−) patients; Model 2: LOS for KPC(+)
and KPC(−) patients, adjusted for insect virulence score; Model 3: LOS
for KPC(+) and KPC(−) patients adjusted for insect virulence score, and
transfer to ICU post culture. KPC = Klebsiella pneumoniae producing
carbapenemase, LOS = length of stay.
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virulence. There is a need for further studies with in-
creased power to fully elucidate the clinical virulence of
KPC(+) K. pneumoniae.
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